JP2002516900A5 - - Google Patents

Download PDF

Info

Publication number
JP2002516900A5
JP2002516900A5 JP2000552085A JP2000552085A JP2002516900A5 JP 2002516900 A5 JP2002516900 A5 JP 2002516900A5 JP 2000552085 A JP2000552085 A JP 2000552085A JP 2000552085 A JP2000552085 A JP 2000552085A JP 2002516900 A5 JP2002516900 A5 JP 2002516900A5
Authority
JP
Japan
Prior art keywords
compound
solvate
pharmaceutically acceptable
preparing
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000552085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002516900A (ja
JP3554539B2 (ja
Filing date
Publication date
Priority claimed from SE9801992A external-priority patent/SE9801992D0/xx
Application filed filed Critical
Publication of JP2002516900A publication Critical patent/JP2002516900A/ja
Application granted granted Critical
Publication of JP3554539B2 publication Critical patent/JP3554539B2/ja
Publication of JP2002516900A5 publication Critical patent/JP2002516900A5/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000552085A 1998-06-04 1999-05-31 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉ Expired - Fee Related JP3554539B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9801992-0 1998-06-04
SE9801992A SE9801992D0 (sv) 1998-06-04 1998-06-04 New 3-aryl-2-hydroxypropionic acid derivative I
PCT/SE1999/000941 WO1999062872A1 (en) 1998-06-04 1999-05-31 New 3-aryl-2-hydroxypropionic acid derivative (i)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2003273428A Division JP2004043480A (ja) 1998-06-04 2003-07-11 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉの中間体

Publications (3)

Publication Number Publication Date
JP2002516900A JP2002516900A (ja) 2002-06-11
JP3554539B2 JP3554539B2 (ja) 2004-08-18
JP2002516900A5 true JP2002516900A5 (https=) 2005-04-28

Family

ID=20411587

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000552085A Expired - Fee Related JP3554539B2 (ja) 1998-06-04 1999-05-31 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉ
JP2003273428A Withdrawn JP2004043480A (ja) 1998-06-04 2003-07-11 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉの中間体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003273428A Withdrawn JP2004043480A (ja) 1998-06-04 2003-07-11 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉの中間体

Country Status (39)

Country Link
US (5) US6258850B1 (https=)
EP (1) EP1084103B1 (https=)
JP (2) JP3554539B2 (https=)
KR (1) KR100625152B1 (https=)
CN (2) CN1311772A (https=)
AR (2) AR020875A1 (https=)
AT (1) ATE246674T1 (https=)
AU (1) AU752261B2 (https=)
BR (1) BR9910928A (https=)
CA (1) CA2333938C (https=)
CZ (1) CZ297424B6 (https=)
DE (1) DE69910203T2 (https=)
DK (1) DK1084103T3 (https=)
DZ (1) DZ2800A1 (https=)
EE (1) EE04772B1 (https=)
EG (1) EG24140A (https=)
ES (1) ES2205844T3 (https=)
HR (1) HRP20000782B1 (https=)
HU (1) HUP0103376A3 (https=)
ID (1) ID28833A (https=)
IL (1) IL139636A (https=)
IS (1) IS2071B (https=)
MA (1) MA26635A1 (https=)
MY (1) MY117785A (https=)
NO (1) NO323426B1 (https=)
NZ (1) NZ508452A (https=)
PL (1) PL195189B1 (https=)
PT (1) PT1084103E (https=)
RS (1) RS49688B (https=)
RU (1) RU2214999C2 (https=)
SA (1) SA99200304B1 (https=)
SE (1) SE9801992D0 (https=)
SK (1) SK284642B6 (https=)
TN (1) TNSN99108A1 (https=)
TR (1) TR200003581T2 (https=)
TW (1) TW446696B (https=)
UA (1) UA71912C2 (https=)
WO (1) WO1999062872A1 (https=)
ZA (1) ZA200006774B (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8702758D0 (en) * 1987-02-06 1987-03-11 Wellcome Found Treatment of disease
DE122007000044I2 (de) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
CN1280574A (zh) * 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
SE9904415D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New process
CA2392038A1 (en) * 1999-12-03 2001-06-07 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
SE9904421D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New compounds
US7084177B2 (en) * 1999-12-03 2006-08-01 Astrazeneca Ab Comminuted form of(S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid
TW574193B (en) 1999-12-03 2004-02-01 Astrazeneca Ab Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses
WO2001051078A1 (en) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
US6559335B2 (en) 2000-09-22 2003-05-06 Dr. Reddy's Laboratories Limited Process for the preparation of 3-aryl-2-hydroxy propanoic acid
EP1354602B1 (en) 2000-12-26 2006-10-04 Sankyo Company, Limited Medicinal compositions containing diuretic and insulin resistance-improving agent
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
JP2004528388A (ja) * 2001-06-01 2004-09-16 アストラゼネカ アクチボラグ ３−アリール−２−ヒドロキシプロピオン酸誘導体の製造法
SE0101980D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101981D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101978D0 (sv) 2001-06-01 2001-06-01 Astrazeneca Ab New compounds
CZ20033309A3 (cs) 2001-06-07 2004-05-12 Eliálillyáandácompany Modulátory receptorů aktivovaných peroxizomálními proliferátory }PPARB
CN101444496B (zh) * 2001-06-12 2011-04-13 维尔斯达医疗公司 用于治疗代谢失调的化合物
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
SE0201005D0 (sv) * 2002-04-02 2002-04-02 Astrazeneca Ab New Process
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
US7351858B2 (en) * 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
SE0201937D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
SE0201936D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
BR0311932A (pt) * 2002-06-20 2005-03-22 Astrazeneca Ab Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
BRPI0411409A (pt) * 2003-06-06 2006-07-25 Cadila Healthcare Ltd processo para a preparação de derivados de ácido propanóico e processo para a preparação de um composto tendo a fórmula (1a)
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314078D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
US20070142472A1 (en) * 2003-11-27 2007-06-21 Tohru Yokozawa Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
KR20060133084A (ko) 2004-04-03 2006-12-22 아스트라제네카 아베 치료제
FR2872159B1 (fr) * 2004-06-28 2007-10-05 Merck Sante Soc Par Actions Si Nouveaux derives acides carboxyliques phenyliques et leur utilisation dans le traitement du diabete
TW200608967A (en) 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
EP1874308A1 (en) * 2005-03-08 2008-01-09 Nycomed GmbH Roflumilast for the treatment of diabetes mellitus
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
GB2454615A (en) * 2006-07-21 2009-05-13 Lupin Ltd Antidiabetic azabicyclo (3.1.0) hexan compounds
KR100958831B1 (ko) * 2006-09-19 2010-05-24 주식회사유한양행 헤테로아릴피리미딘 유도체, 이들의 제조방법, 및 이들을포함하는 조성물
US20090082441A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched tesaglitazar
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
ES2687027T3 (es) 2010-11-04 2018-10-23 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepáticas
DK2637646T3 (en) 2010-11-08 2016-08-29 Albireo Ab PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
ES2861268T3 (es) 2011-09-20 2021-10-06 Basf Se Moduladores de bajo peso molecular del receptor de mentol frío TRPM8 y su uso
US20160024540A1 (en) * 2013-03-27 2016-01-28 Pfizer Ireland Pharmaceuticals Process and Intermediates for the Preparation of Pregabalin
US9562012B2 (en) * 2013-07-22 2017-02-07 Metabolic Solutions Development Company, Llc PPAR-sparing compounds for the treatment of metabolic diseases
AU2023376551A1 (en) 2022-11-08 2025-04-17 Genfit Ppar-alpha/gamma agonist for use in the treatment of liver failure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4114417A (en) * 1977-06-27 1978-09-19 Schmelzer Corporation Method and apparatus for making metal parts
US4479005A (en) * 1982-12-16 1984-10-23 The Dow Chemical Company Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
FR2653119B1 (fr) 1989-10-18 1994-08-05 Lipha Nouveaux aryloxy alcoyl benzenes, leurs procedes de preparation et les compositions pharmaceutiques en renfermant.
US5068345A (en) * 1989-10-30 1991-11-26 Eastman Kodak Company Oxazolidinone aldol adduct
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9114948D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CZ1095A3 (en) * 1992-07-03 1995-10-18 Smithkline Beecham Plc Heterocyclic compounds, process of their preparation, their use for the preparation of a pharmaceutical preparation and the pharmaceutical composition containing thereof
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5648541A (en) * 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
KR20000005224A (ko) * 1996-04-04 2000-01-25 가와무라 요시부미 페닐알킬카르복실산 유도체_
MXPA00004036A (es) * 1997-10-27 2006-05-24 Reddys Lab Ltd Dr Compuestos triciclicos novedosos y su uso en medicina; proceso para su preparacion y composiciones farmaceuticas que los contienen..
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I

Similar Documents

Publication Publication Date Title
JP2002516900A5 (https=)
RU2214999C2 (ru) Производное 3-арил-2-гидроксипропионовой кислоты, способ его получения(варианты), фармацевтический препарат, способ лечения и промежуточный продукт
RU2000130189A (ru) Новое производное i 3-арил-2-гидроксипропионовой кислоты
EP0668851B1 (en) A novel arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent
JP2002508375A5 (https=)
CS208664B2 (en) Method of making the new r,s-n-/2-phenyl-2-hydroxyethyl/-1-alkyl-3-/4-substituted phenyl/propylamines
JP2002513793A5 (https=)
HUP0200929A2 (en) Thiazolidinedione derivative and its use as antidiabetic and process for preparation thereof
JP6215399B2 (ja) ナルトレキソンの製造方法
JP2009161544A (ja) チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
JPH0681723B2 (ja) 非−白金抗癌薬によりひき起こされる嘔吐の軽減用治療剤
JP2005513014A5 (https=)
US6939856B2 (en) Method for preparing dexchlor tannate
KR20040020926A (ko) 중수소화된 엔-치환 및 α-치환 디페닐알콕시 아세트산아미노 알킬 에스테르 및 이 화합물을 포함한 의약품
MXPA01010822A (es) Composicion farmaceutica novedosa.
CA1172170A (en) Antiviral alpha, alpha-dialkyl adamantylethylamines
JPH0725724B2 (ja) トラネキサム酸亜鉛化合物
KR100601244B1 (ko) 티아졸리딘디온 유도체 및 그의 당뇨병약으로서의 용도
RU2007143025A (ru) Полиморфизм додекагидроклопента[а]фенантренилового эфира тиофенкарбоновой кислоты
JP2003519683A5 (https=)
JP2004532265A5 (https=)
EP0030023A3 (en) A heterocyclic compound and its synthesis, pharmaceutical formulations thereof and the use of the compounds and the formulations in medicine
HUP0203790A2 (hu) (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére
JP2003520835A5 (https=)
EP0246888A3 (en) Dopamine-beta-hydroxylase inhibitors